Ropes & Gray Helps Pfizer Buy Anti-Scar Drug Co.

Law360, New York (November 22, 2011, 2:59 PM EST) -- Pfizer Inc. has agreed to purchase Excaliard Pharmaceuticals Inc., a privately held specialty drug company that focuses on treatments for skin scars, for an undisclosed amount, the drug giant announced Tuesday.

Despite not announcing a purchase price, Pfizer said that it will give Excaliard an upfront payment and contingent payments for meeting certain milestones. Excaliard's lead product, EXC 001, is in Phase 2 testing, and will fill a hole in the treatment of excessive scarring.

There are no U.S. Food and Drug Administration-approved treatments for skin...
To view the full article, register now.